ArticleInternational journal of pharmaceutics: X2025
Ionto phoretic delivery of caspofungin acetate to the cornea and sclera and its intracorneal biodistribution.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Iontophoresis Drug Delivery to the Macula of Lutein for Age Related Macular Degeneration.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Caspofungin (CAS) is a potent antifungal agent belonging to the echinocandin family. It is a water-soluble dication at physiological pH, making it a good candidate for iontophoresis. Intracorneal iontophoretic delivery and biodistribution of CAS and its electrically assisted transport into the sclera were investigated as a function of experimental conditions, including donor concentration (1, 5 and 10 mg/mL) and application time (5 and 20 min) using an in-house set-up (with Ag/AgCl electrodes) and a marketed iontophoretic applicator (Iontofor CXL®) that used inert (stainless steel) electrodes. CAS deposition after passive delivery for 20 min (10 mg/mL) was 64.9 ± 23.7 μg/cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.